ExpreS2ion Biotech Holding AB (publ)

Stockholm Stock Exchange EXPRS2.ST

ExpreS2ion Biotech Holding AB (publ) EBIT Margin for the year ending December 31, 2023: -1,410.87%

ExpreS2ion Biotech Holding AB (publ) EBIT Margin is -1,410.87% for the year ending December 31, 2023, a 42.92% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

ExpreS2ion Biotech Holding AB (publ) EBIT Margin for the year ending December 31, 2022 was -2,471.69%, a -527.53% change year over year.
ExpreS2ion Biotech Holding AB (publ) EBIT Margin for the year ending December 31, 2021 was -393.88%, a 34.01% change year over year.
ExpreS2ion Biotech Holding AB (publ) EBIT Margin for the year ending December 31, 2020 was -596.88%, a -355.63% change year over year.
ExpreS2ion Biotech Holding AB (publ) EBIT Margin for the year ending December 31, 2019 was -131.00%, a 31.30% change year over year.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

Stockholm Stock Exchange: EXPRS2.ST

ExpreS2ion Biotech Holding AB (publ)

CEO	Mr. Bent U. Frandsen MSc
IPO Date	July 29, 2016
Location	Denmark
Headquarters	SCION-DTU Science Park
Employees	18
Sector	Health Care
Industries Biotechnology Pharmaceuticals Vaccines

Description

ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops and produces complex proteins for vaccines and diagnostics in Denmark. The company develops capsid virus-like particle COVID-19 vaccine, which is in Phase II clinical trial. It also develops influenza and breast cancer vaccine, which is in Phase II clinical trial, as well as develops malaria vaccine. In addition, the company licenses its ExpreS2 platform to research institutes and pharmaceutical companies. ExpreS2ion Biotech Holding AB (publ) was founded in 2015 is based in Horsholm, Denmark.

Key trends

Past 5 years